Ph-positive stem cells (CD34+) from patients with chronic phase CML are equally resistant to the drug (294) and exhibit enhanced MAP kinase activity after treatment (295). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.